Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by TexRitteron Aug 27, 2018 8:19pm
191 Views
Post# 28526453

RE:RE:RE:Deal with.....pharma

RE:RE:RE:Deal with.....pharmaAgreed, Nathan - but I do think - if the next 2 earnings reports show continued growth of med sales coupled with more positive test results related to cannabis med use, big pharma companies will move earlier than the norm - they will not want to be last to the dance. Medical is growing in small market Canada, but also Europe, and if it continues to look like the US will follow, a big first investment would make sense then I think. ACB has set itself up very well medically now, and I think the next couple of earnings will show that. Money will be helpful to market rec, but I think our strengths will start to shine in the next 12 months. It'll be nice if a big deal comes soon, but I think one will come, now or later, provided things continue on the current path. In a substantial way, the purchases of Cannimed and MedReleaf - which cost us in terms of short term share price - should help twofold: creating a big medical presence, and marketing ACB for the coming rec market. When people are prescribed med cannabis by doctors now, more often than not they go with what they believe are the oldest, most reliable names: those are Cannimed and MedReleaf, both prescriptions soon to be Aurora. THe more the name is out there, the more prevalent it will be for new clientele in the rec market. Exciting times.
Bullboard Posts